Quality Systems – Page 270

Backing Delamination during scale-up: root cause mapping across materials and process

Understanding Backing Delamination during Scale-Up: A Structured Approach to Root Cause Investigation Backing delamination during scale-up is a critical problem in the pharmaceutical manufacturing process, particularly within transdermal drug delivery…

Sterility Test Failure during aseptic filling: FDA-ready investigation report and batch disposition

Sterility Test Failure Investigation Report for Aseptic Filling In the pharmaceutical manufacturing industry, sterility test failures during aseptic filling operations can lead to significant concerns regarding product quality and patient…

Curling After Packaging during scale-up: process parameter review and validation impact

Curling After Packaging During Scale-Up: A Comprehensive Investigation Approach The detection of curling post-packaging in transdermal drug delivery systems during scale-up poses significant challenges to pharmaceutical manufacturers. The curling phenomenon…

Dose Delivery Variability during die-cutting: inspection-ready documentation pack

Addressing Dose Delivery Variability during the Die-Cutting Process: A Comprehensive Investigation Framework In pharmaceutical manufacturing, dose delivery variability can severely impact product efficacy and patient safety. During the die-cutting process,…

Residual Solvent Oos during EU/UK market supply: packaging integrity and shelf-life justification

Addressing Residual Solvent OOS During EU/UK Market Supply: Insights into Packaging Integrity and Shelf-Life Justification In the realm of pharmaceutical manufacturing, the detection of a residual solvent Out of Specification…

Ph Drift during method transfer: packaging integrity and CCIT justification

Understanding pH Drift During Method Transfer: Addressing Packaging Integrity and CCIT Justification In the pharmaceutical industry, pH drift during method transfer can lead to significant quality control challenges, particularly for…

Edge Lifting after adhesive change: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Edge Lifting Issues Post-Adhesive Change In pharmaceutical manufacturing, particularly within transdermal drug delivery systems, the integrity of adhesive bonds is critical. A common issue…

Dose Delivery Variability in transdermal patch manufacturing: inspection-ready documentation pack

Addressing Dose Delivery Variability in the Manufacturing of Transdermal Patches Dose delivery variability in transdermal patch manufacturing presents significant challenges, often manifesting as deviations or out-of-specification (OOS) results. This article…

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Addressing Pet Failures During PAI Readiness with Effective CAPA Implementation In pharmaceutical manufacturing, particularly with ophthalmic dosage forms, the readiness for a Pre-Approval Inspection (PAI) is critical. One widespread issue…

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Investigating Packaging Dry-Out Issues during Die-Cutting in Pharmaceutical Manufacturing In the dynamic environment of pharmaceutical manufacturing, particularly in the production of transdermal drug delivery systems, challenges such as packaging dry-out…

Assay Oos after adhesive change: GMP investigation plan and CAPA

Investigation Plan and CAPA for Assay OOS Following Adhesive Change Investigating Out-of-Specification (OOS) assay results after an adhesive change presents a critical challenge in pharmaceutical manufacturing. Such deviations can signify…

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Ivpt Failures in Transdermal Patch Manufacturing In the pharmaceutical industry, ensuring consistent product quality is paramount, especially in the manufacturing of transdermal patches. An…